(Q44239112)

1 December 2017

title

Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma (English)

1 reference

1 December 2017

1 reference

2

Ian F Tannock

1 reference

ORCID Public Data File 2021

1 December 2017

1 reference

author name string

Brigette B Y Ma

1

1 reference

1 December 2017

Gregory R Pond

3

1 reference

1 December 2017

Matthew R Edmonds

4

1 reference

1 December 2017

Lillian L Siu

5

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

1 December 2017

1 reference

1 December 2017

volume

95

1 reference

1 December 2017

issue

12

1 reference

1 December 2017

page(s)

2516-2523

1 reference

The role of chemotherapy in the management of nasopharyngeal carcinoma

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10995

7 January 2021

Cancer mortality of Chinese in Canada.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10995

7 January 2021

Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10995

7 January 2021

Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10995

7 January 2021

Phase I/II study of the CAPABLE regimen for patients with poorly differentiated carcinoma of the nasopharynx

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10995

7 January 2021

A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10995

7 January 2021

Outpatient weekly chemotherapy in patients with nasopharyngeal carcinoma and distant metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10995

7 January 2021

A phase II study of carboplatin in nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10995

7 January 2021

Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10995

7 January 2021

Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10995

7 January 2021

A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10995

7 January 2021

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10995

7 January 2021

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10995

7 January 2021

Chemotherapy enhances endothelial cell reactivity to platelets

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10995

7 January 2021

Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10995

7 January 2021

Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10995

7 January 2021

The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10995

7 January 2021

A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10995

7 January 2021

Identifiers

DOI

10.1002/CNCR.10995

1 reference

1 December 2017

1 reference